Newsroom

Stay up to date with what’s happening at ONO PHARMA USA.

Doctor meeting with a patient
Ono Pharmaceutical Co., Ltd. Supports for Relief Efforts in the Earthquake in Turkey and Syria
Company
February 17, 2023
Ono Pharmaceutical Co., Ltd. Announced 2022 3Q Financial Results
Company
January 31, 2023
Ono Pharmaceutical Co., Ltd. Acquires Multiple Research-Stage Oncology Programs from KSQ Therapeutics
Licensing
January 25, 2023
Ono Pharmaceutical Co., Ltd. Selected as a Highest Rating A-List Company for Both “Climate Change” and “Water Security” in CDP 2022
Sustainability
December 27, 2022
Ono Pharmaceutical Co., Ltd. Selected for the DJSI World Index and DJSI Asia Pacific Index for Three Straight Years
Sustainability
December 27, 2022
Ono Pharmaceutical Co., Ltd. and Equillium Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab
Licensing
December 6, 2022
Ono Pharmaceutical Co., Ltd. Announced 2022 2Q Financial Results
Company
October 31, 2022
ONO PHARMA USA continues to expand its organization for enhancement of R&D activities and future commercialization opportunities in the U.S.
Company
August 31, 2022
ONO PHARMA USA Initiated Phase 1 Study of ONO-7018, a MALT1 Inhibitor,in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia in the U.S.
R & D
August 29, 2022
Ono Pharmaceutical Co., Ltd. Announced 2022 1Q Financial Results
Company
August 1, 2022